{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:12:46Z","timestamp":1788401566699,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002958","name":"Drug Applied Research Center, Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.humimm.2024.110769","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T08:16:33Z","timestamp":1709194593000},"page":"110769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The inhibition of ADAM17 in cord blood stem cell-derived CD16+ NK cells to enhance their cytotoxicity against acute lymphoblastic leukemia cells"],"prefix":"10.1016","volume":"85","author":[{"given":"Behnaz","family":"Valipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Momeneh","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abedelahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojjatollah Nozad","family":"Charoudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.humimm.2024.110769_b0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S2352-4642(18)30066-X","article-title":"Global efforts toward the cure of childhood acute lymphoblastic leukaemia","volume":"2","author":"Pui","year":"2018","journal-title":"Lancet Child Adolescent Health"},{"issue":"1","key":"10.1016\/j.humimm.2024.110769_b0010","first-page":"41","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"Li","year":"2020","journal-title":"Blood, J. Am. Soc. Hematology"},{"key":"10.1016\/j.humimm.2024.110769_b0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.canlet.2020.01.008","article-title":"DNA damage response and resistance of cancer stem cells","volume":"474","author":"Abad","year":"2020","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.humimm.2024.110769_b0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.it.2018.12.003","article-title":"The emergence of natural killer cells as a major target in cancer immunotherapy","volume":"40","author":"Souza-Fonseca-Guimaraes","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.humimm.2024.110769_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117223","article-title":"Cord blood stem cell derived CD16+ NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody","volume":"242","author":"Valipour","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.humimm.2024.110769_b0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.humimm.2024.110769_b0035","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.141.10.3478","article-title":"Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes","volume":"141","author":"Lanier","year":"1988","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2024.110769_b0040","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.humimm.2024.110769_b0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000132568","article-title":"Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines","volume":"29","author":"Kim","year":"2008","journal-title":"Tumor Biol."},{"issue":"18","key":"10.1016\/j.humimm.2024.110769_b0050","first-page":"3599","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood J. Am. Soc. Hematology"},{"key":"10.1016\/j.humimm.2024.110769_b0055","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9673537","article-title":"Recent advances in ADAM17 research: a promising target for cancer and inflammation","volume":"2017","author":"Moss","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"42","key":"10.1016\/j.humimm.2024.110769_b0060","doi-asserted-by":"crossref","first-page":"44151","DOI":"10.18632\/oncotarget.6629","article-title":"Cytokine secretion and NK cell activity in human ADAM17 deficiency","volume":"6","author":"Tsukerman","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.humimm.2024.110769_b0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A genetically engineered primary human natural killer cell platform for cancer immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.humimm.2024.110769_b0070","doi-asserted-by":"crossref","first-page":"e1115178","DOI":"10.1080\/2162402X.2015.1115178","article-title":"Advances in clinical NK cell studies: donor selection, manufacturing and quality control","volume":"5","author":"Koehl","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.humimm.2024.110769_b0075","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fimmu.2017.00676","article-title":"A two-phase expansion protocol combining interleukin (IL)-15 and IL-21 improves natural killer cell proliferation and cytotoxicity against rhabdomyosarcoma","volume":"8","author":"Wagner","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2024.110769_b0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.15171\/apb.2016.022","article-title":"Key immune cell cytokines affects the telomere activity of cord blood cells in vitro","volume":"6","author":"Brazvan","year":"2016","journal-title":"Advanced Pharmaceutical Bulletin"},{"issue":"15","key":"10.1016\/j.humimm.2024.110769_b0085","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","article-title":"Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients","volume":"23","author":"Dolstra","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.humimm.2024.110769_b0090","doi-asserted-by":"crossref","first-page":"e1017701","DOI":"10.1080\/2162402X.2015.1017701","article-title":"Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer","volume":"4","author":"Cany","year":"2015","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.humimm.2024.110769_b0095","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1172\/JCI64837","article-title":"Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity","volume":"122","author":"Grier","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.humimm.2024.110769_b0100","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/cancers12040952","article-title":"Natural killer cells: tumor surveillance and signaling","volume":"12","author":"Meza Guzman","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.humimm.2024.110769_b0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.12095","article-title":"Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy","volume":"173","author":"Zhou","year":"2013","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2024.110769_b0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","article-title":"The roles of IFN\u03b3 in protection against tumor development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.humimm.2024.110769_b0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3934\/medsci.2020011","article-title":"Sensitization to cell death induced by soluble fas ligand and agonistic antibodies with exogenous agents: a review","volume":"7","author":"Muraki","year":"2020","journal-title":"AIMS Medical Science"},{"issue":"1","key":"10.1016\/j.humimm.2024.110769_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.humimm.2024.110769_b0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47\u2013SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"6","key":"10.1016\/j.humimm.2024.110769_b0130","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/JLB.2MR1218-501R","article-title":"Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy","volume":"105","author":"Wu","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.humimm.2024.110769_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107465","article-title":"The past, present and future perspectives of matrix metalloproteinase inhibitors","volume":"207","author":"Li","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.humimm.2024.110769_b0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fimmu.2020.00073","article-title":"Tumor microenvironment-associated extracellular matrix components regulate NK cell function","volume":"11","author":"Rossi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110769_b0145","article-title":"Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: a minireview","author":"Mondal","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.humimm.2024.110769_b0150","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrd2308","article-title":"Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases","volume":"6","author":"Hu","year":"2007","journal-title":"Nature Reviews Drug Discovery"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924000259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924000259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:05:07Z","timestamp":1781568307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924000259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0198885924000259"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110769","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The inhibition of ADAM17 in cord blood stem cell-derived CD16+ NK cells to enhance their cytotoxicity against acute lymphoblastic leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110769"}}